Key Points
- Omada Health CEO Sean Duffy sold 40,796 shares on Jan. 13 at an average price of $15.95, netting about $650,696 and reducing his stake by 24.36% to 126,644 shares (worth roughly $2.02M).
- Shares traded down about 3.9% (around $15.50) with a 12‑month range of $14.14–$28.40 and a market cap near $898M; analysts maintain a “Moderate Buy” consensus with an average target of $25.40 (8 Buy / 3 Hold / 1 Sell).
Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CEO Sean Duffy sold 40,796 shares of the business's stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $15.95, for a total value of $650,696.20. Following the completion of the sale, the chief executive officer directly owned 126,644 shares in the company, valued at $2,019,971.80. This trade represents a 24.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Omada Health Trading Down 3.9%
NASDAQ OMDA opened at $15.50 on Thursday. Omada Health, Inc. has a 12 month low of $14.14 and a 12 month high of $28.40. The stock's fifty day moving average price is $17.06 and its 200-day moving average price is $20.01. The stock has a market cap of $897.61 million and a P/E ratio of -62.00.
Wall Street Analysts Forecast Growth
OMDA has been the subject of several recent analyst reports. Morgan Stanley set a $32.00 target price on shares of Omada Health in a report on Thursday, December 18th. Wells Fargo & Company assumed coverage on shares of Omada Health in a research report on Thursday, January 8th. They set an "equal weight" rating and a $17.00 price target for the company. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Omada Health in a research report on Wednesday, October 8th. Evercore ISI increased their target price on Omada Health from $27.00 to $28.00 and gave the company an "outperform" rating in a research note on Friday, November 7th. Finally, BMO Capital Markets started coverage on Omada Health in a report on Thursday, November 13th. They issued an "outperform" rating and a $27.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Omada Health has a consensus rating of "Moderate Buy" and an average price target of $25.40.
Get Our Latest Research Report on Omada Health
Institutional Investors Weigh In On Omada Health
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. bought a new stake in Omada Health in the 2nd quarter worth approximately $32,000. Strs Ohio bought a new position in shares of Omada Health during the 3rd quarter valued at $38,000. Rakuten Investment Management Inc. purchased a new position in shares of Omada Health in the 3rd quarter worth $49,000. JPMorgan Chase & Co. bought a new stake in shares of Omada Health in the third quarter worth $82,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Omada Health in the third quarter worth $95,000.
About Omada Health
(
Get Free Report)
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
